IndraLab

Statements

Tofacitinib inhibits TYK2. 27 / 27
16 1 | 1 9
reach
"Finally, we found that TYK2/JAK2-dependent IL-12-STAT4 signaling in human PBMC-derived T-blasts was inhibited by both BMS-986165 and tofacitinib, but not VVD-118313 (Fig. 4e)."
36097295
tas
No evidence text available
24461299
reach
"With an EC50 of 5 nM, tofacitinib inhibits JAK3 and TYK2, reducing inflammatory cytokines associated with RA such as IL-2, IL-4, IL-6, and IL-7."
35444538
tas
No evidence text available
21105711
reach
"Tofacitinib potently inhibits JAK1, JAK2, and JAK3 and, to a lesser extent, TYK2 in biochemical assay (IC50 = 3.2, 4.1, 1.6, and 34 nM respectively)."
32326669
eidos
"With an EC 50 of 5 nM , tofacitinib inhibits JAK3 and TYK2 , reducing inflammatory cytokines associated with RA such as IL-2 , IL-4 , IL-6 , and IL-7 ."
35444538
reach
"Thus, tofacitinib that inhibits JAK1, JAK2, JAK3 and, to a lesser extent, TYK2 is used in the clinic for treating RA patients in many countries."
28456914
tas
No evidence text available
tas
No evidence text available
29156136
dgi
No evidence text available
reach
"Tofacitinib inhibits JAK1 and JAK2 to a greater degree than was initially thought and also inhibits Tyk2 marginally."
| PMC
tas
No evidence text available
19053756
tas
No evidence text available
23668484
tas
No evidence text available
22591402
tas
No evidence text available
21106455
reach
"Tofacitinib preferentially inhibits JAK1 and JAK3 and, to a lesser extent, JAK2 and TYK2."
34824210
tas
No evidence text available
26927423
tas
No evidence text available
23214979
tas
No evidence text available
23659214
reach
"Tofacitinib has been shown to inhibit the activity of JAK1, JAK2, and JAK3, and to a lesser extent tyrosine-protein 2 kinases (TyK2)."
| PMC
tas
No evidence text available
18183025
tas
No evidence text available
29298069
tas
No evidence text available
24417533
tas
No evidence text available
22037378
tas
No evidence text available
24398382
reach
"Tofacitinib inhibits JAK1 and JAK2 to a greater degree than was initially thought and also inhibits Tyk2 marginally.139, 140, 141, 142, 143, 144Tofacitinib is the most potent (inhibitory potency of 1 nM) and selective JAK3 inhibitor developed to date."
| PMC
reach
"In kinase assays, tofacitinib, inhibits JAK1, JAK2, JAK3, and to a lesser extent TyK2."
33906853